The down-regulation of IGF2BP1 also can render cancer cells resistant to gemcitabine, taxol, and taxanes in pancreatic cancer, nasopharyngeal carcinoma, and ovarian cancer.224, 225, 226 Zhang et al found that IGF2BP1 could bind to the m6A site on the 3′-UTR of the mRNA of lactate dehydrogenase-A (LDHA), a glycolysis rate-limiting enzyme, and enhance its stability. The gene discussed is IGF2BP1; the disease is cancer.